{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-005080","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2025-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.569057+00:00","generated_at":"2026-05-26T12:52:59.466680+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ionis Q4 rev $227M, FY rev $705M; 2025 guidance rev >$600M, non-GAAP op loss <$495M","bullets":["FY2024 total revenue $705M exceeded guidance; operating loss $475M GAAP, $345M non-GAAP.","WAINUA launched Jan 2024: $85M product sales, $20M royalties; 84% QoQ growth in Q4.","TRYNGOLZA approved Dec 19, 2024 for FCS; first independent launch underway.","Donidalorsen PDUFA date Aug 21, 2025 for HAE; OLE data shows 96% sustained mean attack rate reduction.","2025 guidance: revenue >$600M, non-GAAP op loss <$495M, cash ~$1.7B."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-005080","json":"https://secwatch.observer/filing/0001140361-25-005080.json","markdown":"https://secwatch.observer/filing/0001140361-25-005080.md","text":"https://secwatch.observer/filing/0001140361-25-005080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036125005080/0001140361-25-005080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036125005080/ef20043828_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T12:52:59.466680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}